EMPLOYMENT AGREEMENTEmployment Agreement • May 6th, 2009 • Zymogenetics Inc • Biological products, (no disgnostic substances) • Washington
This AGREEMENT, dated as of December 9, 2008 (the “Effective Date”), is between ZymoGenetics, Inc., a Washington corporation (as supplemented by Section 13, the “Company”), and Stephen Zaruby (“Executive”).
CO-DEVELOPMENT/CO-PROMOTION AND LICENSE AGREEMENT RELATING TO TYPE-3 INTERFERON FAMILY by and among ZymoGenetics, Inc. and ZymoGenetics, LLC and Bristol-Myers Squibb Company Execution Date: January 12, 2009And License Agreement • May 6th, 2009 • Zymogenetics Inc • Biological products, (no disgnostic substances) • New York
This Co-Development/Co-Promotion and License Agreement relating to Type-3 Interferon Family is made as of the Effective Date by and among ZymoGenetics, Inc., a Washington corporation (“ZGEN”), and ZymoGenetics, LLC, a Delaware limited liability company (“ZG LLC”), and Bristol-Myers Squibb Company, a Delaware corporation (“BMS”). ZGEN and ZG LLC are referred to collectively as “Zymo”, and any obligations attributed to Zymo hereunder shall apply jointly and severally to ZGEN and ZG LLC, however, as the owner of the Core Patents, ZG LLC has the sole right to receive the initial license fee, all Milestone Payments, all royalties and Net Profits.
License and Transfer Agreement for IL-21 ProteinLicense and Transfer Agreement • May 6th, 2009 • Zymogenetics Inc • Biological products, (no disgnostic substances) • Washington
This License and Transfer Agreement for IL-21 Protein (“Agreement”) is effective as of January 16, 2009 (the “Effective Date”) and is entered into by and between ZymoGenetics, Inc., a Washington corporation having a principal place of business at 1201 Eastlake Avenue East, Seattle, Washington 98102 (“ZGEN”), and Novo Nordisk A/S, a Danish corporation having a principal place of business at Novo Alle, DK-2880, Bagsvaerd, Denmark (“NN”).
